<DOC>
	<DOCNO>NCT01208818</DOCNO>
	<brief_summary>MYRE phase III multicentric control national clinical trial conduct patient multiple myeloma renal failure relate myeloma cast nephropathy ( MCN ) . Its aim ass ( 1 ) efficacy bortezomib plus dexamethasone ( BD ) , compare cyclophosphamide , plus bortezomib dexamethasone ( C-BD ) patient inaugural MCN require hemodialysis ; ( 2 ) patient inaugural severe renal failure secondary biopsy-proven MCN require hemodialysis intensive hemodialysis regimen use either dialyser high permeability protein ( TheraliteTM ) conventional high-flux dialyser , receive chemotherapy BD .</brief_summary>
	<brief_title>Studies Patients With Multiple Myeloma Renal Failure Due Myeloma Cast Nephropathy</brief_title>
	<detailed_description>MYRE phase III multicentric control national clinical trial conduct patient multiple myeloma renal failure relate myeloma cast nephropathy ( MCN ) . Its aim ass ( 1 ) efficacy bortezomib plus dexamethasone ( BD ) , compare cyclophosphamide , plus bortezomib dexamethasone ( C-BD ) patient inaugural MCN require hemodialysis ; ( 2 ) patient inaugural severe renal failure secondary biopsy-proven MCN require hemodialysis intensive hemodialysis regimen use either dialyser high permeability protein ( TheraliteTM ) conventional high-flux dialyser , receive chemotherapy BD . Study hypotheses : ( 1 ) patient require dialysis , base renal response 3 cycle main endpoint , show benefit 30 % absolute rate expect 30 % response rate control arm ; ( 2 ) patient require hemodialysis , use prevalence patient free dialysis 3 cycle main endpoint , show benefit least 20 % assumed rate 50 % control arm . A total sample size 284 patient compute enrolled ( type I II error rate 5 20 % , respectively ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Immunoglobulin Light Chains</mesh_term>
	<criteria>Age &gt; =18 year old Serum creatinine &gt; 170Âµmol/l and/or DFG &lt; 40 ml/min/1.73 m2 Myeloma cast nephropathy ( MCN ) Multiple myeloma Informed consent neutrophil &gt; = 1 Giga/L platelet &gt; = 70 Giga/L Amylosis Chronic renal Failure eDFG &lt; 30 ml/min/1.73 m2 , unrelated myeloma Peripheral neuropathy Contraindications either corticosteroid Bortezomib Patient refusal Known HIV infection Concomitant severe disease include neoplasia ( except basocellular carcinoma ) Liver failure , cytolysis , and/or cholestasis Fertile woman refuse use effective contraception ; Women pregnant nursing ; Women positive test pregnancy ( test treatment initiation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>